(Q46225985)
Statements
1 reference
FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ONCOLYTIC DELTA-24-RGD (DNX-2401) WITH BIOLOGICAL ENDPOINTS: IMPLICATIONS FOR VIRO- IMMUNOTHERAPY. (English)
1 reference
Frederick F. Lang
Charles Conrad
Cande Gomez-Manzano
Frank Tufaro
WKA Yung
Raymond Sawaya
Sujit Prabhu
Gregory Fuller
Kenneth Aldape
1 July 2014
1 reference